Rufinamide is an antiepileptic drug primarily used to treat seizures associated with Lennox Gastaut syndrome. The efficacy and discontinuation precautions should be combined with the individual situation of the patient. The following provides a detailed explanation from two aspects: treatment efficacy and discontinuation precautions.

1. Therapeutic effect

(1) Overview of therapeutic effects

Lufenamide reduces neuronal overexcitement by regulating sodium channel activity, and has a significant improvement effect on tonic clonic seizures and fall seizures in Lennox Gastaut syndrome.

(2) Clinical data

In key clinical trials, the seizure frequency of patients in the Lufenamide group was reduced by approximately 42.5% compared to the placebo group, and the tolerance was good, making it an adjuvant treatment option for refractory epilepsy.

2. Precautions for discontinuation of medication

(1) Principle of discontinuation of medication

It is necessary to gradually reduce and stop medication under the guidance of a doctor to avoid sudden cessation of medication causing exacerbation of epileptic seizures or status epilepticus. Recommend a reduction period of at least 2-4 weeks.

(2) Monitoring requirements

During the discontinuation of medication, it is necessary to closely monitor the frequency and severity of epileptic seizures. If there is an increase in seizures or abnormal behavioral changes, immediate medical attention should be sought to adjust the plan.

(3) Special populations

Patients with liver dysfunction need to extend the reduction period; Children and elderly patients need to be more cautious when discontinuing medication, and it is recommended to do so under the supervision of a specialist doctor.

(4) Combination medication

When using other antiepileptic drugs at the same time, drug interactions should be considered, and the combined dosage should be adjusted if necessary to reduce the risk of discontinuation.